Biopsy

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Renal cell carcinoma, Trae Elston, Anticipation, Liver disease, Research, Annual general meeting, Safety, Research and development, Therapy, Completeness, Colorectal cancer, Hypertelorism, CRC, Liver, PD, FC, ESMO, Administration, Patient, MSS, Tumor microenvironment, Immunotherapy, G&A, RCC, DCR, TME, Melanoma, Cancer, SITC, Roche, R, Oncology, Phase II, Neoplasm, Society, Cell, Pharming, Biopsy, Medical imaging, Pharmaceutical industry, Vaccine, Cryptocurrency

WALTHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Xilio anticipates activating clinical trial sites for the Phase 1 combination dose escalation in the fourth quarter of 2023.
  • As previously announced, Xilio anticipates reporting preliminary safety data from the Phase 1 clinical trial into the third dose level in the fourth quarter of 2023.
  • General & Administrative (G&A) Expenses: G&A expenses were $6.3 million for the quarter ended September 30, 2023, compared to $7.2 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $16.7 million for the quarter ended September 30, 2023, compared to $19.8 million for the quarter ended September 30, 2022.

Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Pharmaceutical, Health, Webcast, EBITDA, Investment, Element, EPS, Business model, Travers Smith, GAAP, Forecasting, PDUFA, Biopsy, Commercial property, Generic drug, Boston, Ligand

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today.
  • Investment Process: Management provided an overview of Ligand’s investment criteria and due diligence process to source assets with superior risk-reward profiles.
  • Recent Transactions: Management discussed the recent soticlestat and TZIELD (teplizumab) royalty acquisitions, which closed in Q4 2023.
  • Captisol Technology Platform: Management shared that Captisol continues to enable product approvals for Ligand partners, with five possible approvals anticipated in 2024.

Aquyre Biosciences Announces Appointment of Gregory Bowles as President and CEO

Retrieved on: 
Tuesday, December 5, 2023
Biotechnology, General Health, Health, Oncology, Granuloma, Senior, Intuitive Surgical, U.S. Navy Diving Manual, Pathology, National Security Agency, Lymphocyte, University of Michigan, Patient, Marketing, Capital, Lung cancer, Vincent van Gogh, Da Vinci Surgical System, University, Cancer, Diagnosis, DCI, Cell, State, Biopsy, Medical imaging

Aquyre Biosciences, Inc. today announced the appointment of Gregory Bowles as President, Chief Executive Officer and member of the Board of Directors.

Key Points: 
  • Aquyre Biosciences, Inc. today announced the appointment of Gregory Bowles as President, Chief Executive Officer and member of the Board of Directors.
  • At Intuitive Surgical during its early years, he was the Capital Sales Manager where he sold the daVinci Robot in Michigan.
  • Greg’s first startup was EndoGastric Solutions where he held positions as Regional Manager and later as Vice President of Sales.
  • While at Aquyre Biosciences, Greg was the Senior Vice President of Sales and Marketing and has been instrumental in building the company’s commercialization efforts.

Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

Retrieved on: 
Friday, December 1, 2023
Oncology, Medical Supplies, Health, Health Technology, Clinical Trials, Biotechnology, Prostate, Research, Magnetic resonance imaging, Pathology, University, PSA, Risk, Urology, Patient, Prostate cancer, Prostatectomy, Prognosis, Risk assessment, MRI, GRID, Physician, SUO, Society, HIV disease progression rates, Biopsy, Medical imaging

Assessment with the Decipher Prostate Genomic Classifier and biological insights from the Decipher Genomic Resource for Intelligent Discovery (GRID) research tool indicated that Decipher scoring was associated with grade progression, but not volume progression, of prostate cancer.

Key Points: 
  • Assessment with the Decipher Prostate Genomic Classifier and biological insights from the Decipher Genomic Resource for Intelligent Discovery (GRID) research tool indicated that Decipher scoring was associated with grade progression, but not volume progression, of prostate cancer.
  • “We developed the Decipher Prostate Genomic Classifier to provide actionable information that helps guide patient care,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology.
  • “The data presented at SUO 2023 show how users of our test, conducting prospective research on their own patients, affirm the utility of Decipher in real-world settings.
  • We are very grateful for the work conducted by these clinician-scientists on behalf of the entire prostate cancer research community.”

CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024

Retrieved on: 
Thursday, November 30, 2023
Other Health, Research, Managed Care, General Health, Oncology, Medical Devices, Clinical Trials, Science, Biotechnology, Medical Supplies, Other Science, Health, Lung, BIAF, Current Procedural Terminology, PLA, Sputum, Physician, Disease, Clinical trial, CPT, Patient, CD19, LDT, TCPP, Calendar, American Medical Association, Data analysis, CMS, Lung cancer, Flow cytometry, Cancer, Malignancy, Medicare, CEACAM8, CD3, Biopsy, Health insurance, Medical imaging

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.

Key Points: 
  • bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.
  • For the calendar year 2024 Medicare Clinical Lab Fee Schedule, CMS finalized the panel’s recommendation for CyPath® Lung for purposes of payment by Medicare.
  • In November 2023, CMS finalized the 2024 payment determination for CPT 0406U, effective January 1, 2024.
  • “Actionable results from CyPath® Lung may help doctors and their patients determine appropriate next steps for suspected cases of lung cancer,” Ms. Zannes said.

KKR, Hologic and Ajax Health Create New Platform to Accelerate Medical Device Innovation

Retrieved on: 
Thursday, November 30, 2023
Finance, Medical Devices, Health, Professional Services, Health Technology, Breast, Investment, KKR, Prostate Cancer Foundation, Lung cancer, HOLX, Partnership, Growth, Biopsy, Medical imaging, Hologic

KKR, a leading global investment firm, today announced a new platform established with investments from KKR and Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health and medical technology innovator.

Key Points: 
  • KKR, a leading global investment firm, today announced a new platform established with investments from KKR and Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health and medical technology innovator.
  • The new platform, named Maverix Medical, will be managed by Ajax Health under the leadership of Duke Rohlen.
  • Maverix will develop and acquire innovative technologies and commercial operations within the lung cancer disease category.
  • Each year, more people die of lung cancer than of colon, breast and prostate cancers combined.1
    KKR and Ajax Health will contribute existing portfolio company Serpex Medical to the platform.

Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023

Retrieved on: 
Wednesday, November 22, 2023
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, American Cancer Society, PSA, Disease, Urology, Patient, Prostate cancer, MAST, Neoplasm, Prostate-specific antigen, Physician, SUO, Society, Biopsy, Medical imaging, Lace

Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023), where they will demonstrate the clinical performance of Veracyte’s Decipher Prostate Genomic Classifier in identifying patients whose prostate cancer is likely to progress and require treatment.
  • Collectively, the posters will report data from more than 60,000 patients.
  • The American Cancer Society estimates that there will be nearly 290,000 new cases of prostate cancer in the U.S. this year.
  • An ongoing challenge in the management of prostate cancer is distinguishing between patients whose tumors require careful monitoring, known as active surveillance, and those who require intervention.

New Study of an AI-Powered Spectroscopy Device Shows Promise for Skin Cancer Detection

Retrieved on: 
Tuesday, November 21, 2023
Oncology, General Health, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, Other Health, Carcinoma, Sale, Malignancy, Skin cancer, Safety, Hope, Incidence, AUC, ESS, Dermatology, Artificial intelligence, NNB, Data, Patient, Multimedia, FDA, PCP, PPV, Melanoma, NPV, Skin, Overalls, Biopsy, Medical imaging

A newly published study was designed to evaluate the safety and effectiveness of an Elastic Scattering Spectroscopy (ESS) device, the DermaSensor device, in assessing skin lesions suggestive of skin cancer.

Key Points: 
  • A newly published study was designed to evaluate the safety and effectiveness of an Elastic Scattering Spectroscopy (ESS) device, the DermaSensor device, in assessing skin lesions suggestive of skin cancer.
  • These lesions underwent clinical evaluation by expert dermatologists and by the DermaSensor device, a handheld AI-powered spectroscopy device that is non-invasive and wireless.
  • This innovation holds the promise of improving skin cancer care by facilitating expedited and improved detection and intervention.
  • “This study was a key early comparative effectiveness study showing that our device can bring dermatologist-level triage to primary care.

Press Conference: Hundreds of transplant patients, physicians, and health equity advocates expected to rally on Capitol Hill on Tuesday, December 5 to ask President Joe Biden and HHS Secretary Xavier Becerra: "Urgently intervene! Stop private contractors

Retrieved on: 
Wednesday, November 29, 2023
Policy, Transplant, Maryland School, Section, Patient, Transplant surgeon, Fear, Health, University, MD, MPH, Medicare, Administration, Physician, Biopsy, Dentistry, Pharmaceutical industry, Medicine

WASHINGTON, Nov. 29, 2023 /PRNewswire/ -- Honor the Gift, a coalition representing organ transplant patients across the nation, will be joined by Representative Don Bacon (R-NE), the American Association of Kidney Patient's (AAKP) Chair of Policy and Global Affairs Paul T. Conway, Al B Sure!, Executive Chairman of the newly formed "Health Equity in Transplantation Coalition," Rev. Al Sharpton, Senior Advisor, and other leaders in the transplant field, to hold a press conference on December 5, 2023 in the Cannon Caucus Room on Capitol Hill in Washington D.C.

Key Points: 
  • University of Maryland School of Medicine
    In March, transplant patients' regular care was disrupted when a private contractor of Medicare called "MolDX" came between them and their trusted doctors and published an "Article" which tied coverage of non-invasive blood tests to invasive biopsies.
  • The alternative for such blood tests is surgical biopsy procedures, which are more expensive, riskier, and burdensome.
  • For years, transplant doctors could rely on their medical expertise and advanced blood tests to monitor organ transplant injury or rejection, safeguarding patients from invasive biopsies.
  • Now, as Medicare reviews the comments and determines the final decision on coverage, the transplant community is fearful their voices have been ignored and are making a public plea to the Administration.

First Cranial Surgery in Latin America Using Immersive Augmented Reality Surgical Navigation

Retrieved on: 
Wednesday, November 22, 2023
MAC, Brain, Safety, VISAR, Microsoft HoloLens, Anatomy, Cancer, Risk, Surgeon, Spine, Patient, FDA, Neurosurgery, Instrument, Microsoft, Hospital, Biopsy, Dentistry

This surgical procedure marks the first-of-its-kind application of augmented reality surgery in Latin America, showcasing Novarad's commitment to pushing the boundaries of medical science and providing patients with cutting-edge, low-cost treatment options.

Key Points: 
  • This surgical procedure marks the first-of-its-kind application of augmented reality surgery in Latin America, showcasing Novarad's commitment to pushing the boundaries of medical science and providing patients with cutting-edge, low-cost treatment options.
  • In July, surgeons at MAC CDMX Hospital completed a successful spine surgery using VisAR's navigation.
  • Expanding the boundaries of AR navigation, VisAR was utilized in a far more challenging and risky surgery in this case.
  • It allows precise navigation of surgical instruments with optical tracking via an attached code.